---
title: Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome
nct_id: NCT06047574
overall_status: RECRUITING
sponsor: "Shanghai 10th People's Hospital"
study_type: OBSERVATIONAL
primary_condition: Polycystic Ovary Syndrome
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06047574.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06047574"
ct_last_update_post_date: 2026-03-09
last_seen_at: "2026-05-12T06:52:54.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome

**Official Title:** Multidisciplinary Combined Precise Diagnosis and Treatment of Polycystic Ovary Syndrome

**NCT ID:** [NCT06047574](https://clinicaltrials.gov/study/NCT06047574)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 3000
- **Lead Sponsor:** Shanghai 10th People's Hospital
- **Conditions:** Polycystic Ovary Syndrome
- **Start Date:** 2023-09-18
- **Completion Date:** 2026-07-30
- **CT.gov Last Update:** 2026-03-09

## Brief Summary

The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (PCOS) in this study, used statistical software such as SPSS for date analysis, and used experimental techniques such as ELISA and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. Multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a PCOS multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Female aged 18- 45;

Exclusion Criteria:

* Female patients younger than 18 years old or older than 45 years old;
* Ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction;
* Congenital adrenal hyperplasia, reservoir Hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism;
* Abnormal liver or renal function((≥ 3 times of the upper limit of normal range)
* Type 1 diabetes, single gene mutation diabetes, or pancreatic damage Diabetes or other secondary diabetes caused by diabetes;
* History of malignant tumors;
* Severe infection, severe anemia, neutropenia and other systemic chronic diseases;
* Undergo total hysterectomy or ovarian adnexectomy;
* Mental illness, dementia or other cognitive behavioral problems;
* Use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, SGLT-2, and acarbose and GLP-1RA and other drugs;
* Use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, Cyproterone acetate, flutamide, etc.) and other drugs for the treatment of PCOS.
```

## Arms

- **PCOS** — 1. Oligomenorrhea/amenorrhea
2. Clinical androgen excess or biochemical androgen excess
3. Polycystic ovary showed by gynecological ultrasound
- **NOPCOS** — not meet Rotterdam standards

## Interventions

- **This study does not involve any interventions** (OTHER) — This study does not involve any interventions

## Primary Outcomes

- **Fibrinogen-like-protein 1 (FGL1)** _(time frame: baseline)_ — Fibrinogen-like-protein 1 (FGL1), is a novel hepatokine that plays an important role in hepatic steatosis, insulin resistance and obesity. There is no maximum or minimum value for this parameter and the higher scores mean a worse outcome.

## Secondary Outcomes

- **body mass index ,BMI** _(time frame: baseline)_
- **Waist/hip Ratio,WHR** _(time frame: baseline)_
- **Number of menstruation in the last year** _(time frame: baseline)_
- **Ferriman-Gallwey score** _(time frame: Time Frame: baseline)_
- **HOMA-IR** _(time frame: baseline)_
- **TT** _(time frame: baseline)_
- **FT** _(time frame: baseline)_
- **LH** _(time frame: baseline)_
- **FSH** _(time frame: baseline)_
- **FBG** _(time frame: baseline)_
- **PBG** _(time frame: baseline)_
- **FINS** _(time frame: baseline)_
- **PINS** _(time frame: baseline)_
- **AST** _(time frame: baseline)_
- **ALT** _(time frame: baseline)_
- **UA** _(time frame: baseline)_
- **CR** _(time frame: baseline)_
- **LDL-c** _(time frame: baseline)_
- **HDL-c** _(time frame: baseline)_
- **TC** _(time frame: baseline)_
- **TG** _(time frame: baseline)_
- **Interleukin 22#IL-22** _(time frame: baseline)_
- **Interleukin 6#IL-6** _(time frame: baseline)_
- **Interleukin 8# IL-8** _(time frame: baseline)_
- **Tumor Necrosis Factor# TNF** _(time frame: baseline)_
- **Chemerin** _(time frame: baseline)_
- **omentin-1** _(time frame: baseline)_
- **leptin** _(time frame: baseline)_
- **RBP-4** _(time frame: baseline)_
- **adiponectin** _(time frame: baseline)_
- **DHEAS** _(time frame: baseline)_
- **SHBG** _(time frame: baseline)_

## Locations (1)

- Department of Endocrinology, Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of endocrinology, shanghai tenth people's hospital|shanghai|shanghai municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06047574.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06047574*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*